KENNETH ZUCKERMAN, MD
Osteopathic Medicine at Usf Magnolia Dr, Tampa, FL
License number
Florida ME68313
Category
Osteopathic Medicine
Type
Hematology
Address
Address
2
12902 Usf Magnolia Dr, Tampa, FL 33612
PO Box 198441, Atlanta, GA 30384
PO Box 198441, Atlanta, GA 30384
Phone
(813) 745-4673
(866) 761-5658
(866) 761-5658
Personal information
See more information about KENNETH ZUCKERMAN at radaris.comName
Address
Phone
15610 Cochester Rd, Tampa, FL 33647
114 Piedmont C, Delray Beach, FL 33484
15610 Cochester Rd, Tampa, FL 33647
320 Elverton Pl, Jacksonville, FL 32259
1621 Jody Ct, Saint Johns, FL 32259
Organization information
See more information about KENNETH ZUCKERMAN at bizstanding.comKenneth Zuckerman MD
12902 Usf Magnolia Dr, Tampa, FL 33612
Industry:
Internist
Phone:
(813) 745-4673 (Phone)
Kenneth Stuart Zuckerman
Professional information
Dr. Kenneth Zuckerman, Tampa FL - MD (Doctor of Medicine)
Specialties:
Hematology
Address:
Moffitt Cancer Center
12902 Usf Magnolia Dr, Tampa 33612
(813) 745-4673 (Phone), (813) 449-8210 (Fax)
12902 Usf Magnolia Dr, Tampa 33612
(813) 745-4673 (Phone), (813) 449-8210 (Fax)
Certifications:
Hematology, 1978, Internal Medicine, 1975
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Moffitt Cancer Center
12902 Usf Magnolia Dr, Tampa 33612
H. Lee Moffitt Cancer Center and Research Institute I.
12902 Usf Magnolia Dr, Tampa 33612
12902 Usf Magnolia Dr, Tampa 33612
H. Lee Moffitt Cancer Center and Research Institute I.
12902 Usf Magnolia Dr, Tampa 33612
Education:
Medical School
Ohio State University College Of Medicine And Public Health
Graduated: 1972
Ohio State University Hosps
Graduated: 1973
Graduated: 1975
Pb Brigham Hospital Harvard
Graduated: 1978
Ohio State University College Of Medicine And Public Health
Graduated: 1972
Ohio State University Hosps
Graduated: 1973
Graduated: 1975
Pb Brigham Hospital Harvard
Graduated: 1978
Kenneth S Zuckerman, Tampa FL
Specialties:
Internal Medicine, Hematology, Medical Oncology, Hematology
Work:
HLMCC Lifetime Cancer Screening Center
12902 Usf Magnolia Dr, Tampa, FL 33612
12902 Usf Magnolia Dr, Tampa, FL 33612
Education:
The Ohio State University(1972) Internal Medicine
Peptide Antagonists Of Tumor Necrosis Factor Alpha
US Patent:
6344443, Feb 5, 2002
Filed:
Jul 8, 1999
Appl. No.:
09/349661
Inventors:
Richard Y. Liu - Lutz FL
Kenneth S. Zuckerman - Tampa FL
Kenneth S. Zuckerman - Tampa FL
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 3808
US Classification:
514 14, 514 16, 530327, 530329, 435 78
Abstract:
There is provided a method of inhibiting TNF- from binding to TNF receptors by administering an effective amount of an inhibitory peptide. Also provided is a method of inhibiting TNF- functions by administering an effective amount of an inhibitory peptide. There also are provided peptides which have TNF- inhibitory properties. Also provided is a method of inhibiting TNF- binding to TNF receptors by administering an effective amount of peptides having the amino acid sequences shown in SEQ ID No. 1,2,3,4, wherein the peptides can be administered either singly or in combination.
Method For The Modulation Of Function Of Transcription Factors
US Patent:
8178507, May 15, 2012
Filed:
Feb 24, 2009
Appl. No.:
12/391943
Inventors:
Kenneth S. Zuckerman - Tampa FL, US
Richard Y. Liu - Lutz FL, US
Richard Y. Liu - Lutz FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 31/70, C07H 21/02, C07H 21/04, C12Q 1/68
US Classification:
514 44R, 514 44 A, 536 231, 536 241, 536 245
Abstract:
There is provided a method of modulating the function of transcription factor by administering an effective amount of an oligonucleotide containing optimal nucleotide binding sites for the transcription factor. A therapeutic agent having an effective amount of an oligonucleotide for modulating function of transcription factors and a pharmaceutically acceptable carrier is also provided. Also provided is a treatment of patients having illnesses in which the activation of transcription factors play a role by administering to a patient an effective amount of an oligonucleotide which competitively binds the related transcription factor.
Method For The Modulation Of Function Of Transcription Factors
US Patent:
7501401, Mar 10, 2009
Filed:
Feb 21, 2006
Appl. No.:
11/358688
Inventors:
Kenneth S. Zuckerman - Tampa FL, US
Richard Y. Liu - Lutz FL, US
Richard Y. Liu - Lutz FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
A61K 31/70, C07H 21/02, C07H 21/04, C12Q 1/68
US Classification:
514 44, 536 241, 536 245, 435 6, 435375, 435377
Abstract:
There is provided a method of modulating the function of a transcription factor by administering an effective amount of an oligonucleotide containing optimal nucleotide binding site for the transcription factor. A therapeutic agent having an effective amount of an oligonucleotide for modulating function of a transcription factor and a pharmaceutically acceptable carrier is also provided. Also provided is a treatment of patients having illnesses in which the activation of transcription factors plays a role by administering to a patient an effective amount of an oligonucleotide which competitively binds the related transcription factor.
Method For The Inhibition Of Function Of Stat Transcription Factors
US Patent:
7002003, Feb 21, 2006
Filed:
Jul 30, 1999
Appl. No.:
09/744875
Inventors:
Kenneth S. Zuckerman - Tampa FL, US
Richard Y. Liu - Lutz FL, US
Richard Y. Liu - Lutz FL, US
Assignee:
University of South Florida - Tampa FL
International Classification:
C07H 21/04, A61K 48/00, C12N 15/00
US Classification:
536 241, 536 245, 536 231, 514 44
Abstract:
There is provided a method of modulating the function of transcription factor by administering an effective amount of an oligonucleotide containing optimal nucleotide binding sites for the transcription factor. A therapeutic agent having an effective amount of an oligonucleotide for modulating function of transcription factors and a pharmaceutically acceptable carrier is also provided. Also provided is a treatment of patients having illnesses in which the activation of transcription factors play a role by administering to a patient an effective amount of an oligonucleotide which competitively binds the related transcription factor.